59 patents
Utility
Use of Oxygenated Cholesterol Sulfates for Treating Inflammatory Conditions
23 Nov 23
Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia.
Shunlin Ren, Yaping Wang, WeiQi Lin, James E. Brown, Felix Theeuwes
Filed: 25 Jun 21
Utility
Crystalline Thiocholesterol
16 Nov 23
Crystalline forms of thiocholesterol are disclosed herein.
ANDREW R. MIKSZTAL, WEIQI LIN, MICHAEL HOLTZ-MULHOLLAND, JULIETTE SABBATANI, TRAVIS LEE HOUSTON, STEPHAN D. PARENT
Filed: 11 Oct 21
Utility
Crystalline Sodium Cholesteryl Sulfate
16 Nov 23
Crystalline forms of crystalline sodium cholesteryl sulfate are disclosed herein.
WEIQI LIN, STEPHAN D. PARENT, COURTNEY S. JOHNSON
Filed: 11 Oct 21
Utility
Crystalline Sodium Cholesteryl Sulfonate
9 Nov 23
Crystalline and non-crystalline forms of crystalline sodium cholesteryl sulfonate are disclosed herein.
WEIQI LIN, MICHAEL HOLTZ-MULHOLLAND, JULIETTE SABBATANI, JING TENG
Filed: 11 Oct 21
Utility
Uses of Oxygenated Cholesterol Sulfates (Ocs)
5 Oct 23
Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided.
Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
Filed: 28 Feb 23
Utility
Sustained release drug delivery systems with reduced impurities and related methods
3 Oct 23
The present disclosure relates to sustained release drug delivery systems.
Andrew R. Miksztal, Judy Joice, Susan Autio, Mark P. Davis
Filed: 21 Jan 22
Utility
Use of Oxygenated Cholesterol Sulfates for Treating Autoimmune Conditions
21 Sep 23
Aspects of the present disclosure include methods for treating at least one autoimmune condition, such as at least one of hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
Shunlin Ren, Yaping Wang, WeiQi Lin
Filed: 25 Jun 21
Utility
Use of Oxygenated Cholesterol Sulfates for Treating at Least One of Insulin Resistance, Diabetes, and Prediabetes
14 Sep 23
Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH).
Shunlin Ren, Yaping Wang, WeiQi Lin, James E. Brown, Terrence Blaschke
Filed: 25 Jun 21
Utility
Use of Oxygenated Cholesterol Sulfates for Cancers and Non-cancerous Transformations Related to Epstein-barr Virus
27 Jul 23
Aspects of the present disclosure include methods for treating at least one of cancer and non-cancerous transformation related to Epstein-Barr virus, such as at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma.
Shunlin Ren, Yaping Wang, WeiQi Lin
Filed: 25 Jun 21
Utility
Use of Oxygenated Cholesterol Sulfates for Treating Neurological Conditions, Neurodegenerative Diseases, and Addiction
13 Jul 23
Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease.
Shunlin Ren, Yaping Wang, WeiQi Lin, James E. Brown, Felix Theeuwes
Filed: 25 Jun 21
Utility
Depot Formulations
11 May 23
Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
Jeremy C. WRIGHT, Felix THEEUWES, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
Filed: 4 Jan 23
Utility
Treatment of Infectious Diseases
11 May 23
Methods of treating infectious diseases are provided.
SHUNLIN REN, WEIQI LIN, JAMES E. BROWN
Filed: 10 Feb 21
Utility
Uses of oxygenated cholesterol sulfates (OCS)
28 Mar 23
Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided.
Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
Filed: 3 Aug 20
Utility
Crystalline and Liquid Crystalline 25-HYDROXY-CHOLEST-5-EN-3-SULFATE Sodium and Methods for Preparing Same
23 Feb 23
Crystalline and liquid crystalline forms of 25HC3S sodium are described herein.
ANDREW R. MIKSZTAL, SHAWN JOHNSTONE, MICHAEL HOLTZ-MULHOLLAND, FLAVIO LOPEZ, HOWARD SARD, JIE LI, MARIO GONZALEZ, STEPHAN D. PARENT, TRAVIS LEE HOUSTON, ROBERT WENSLOW
Filed: 23 Dec 20
Utility
Compositions Comprising 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) or Pharmaceutically Acceptable Salt Thereof and at Least One Cyclic Oligosaccharide
16 Feb 23
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided.
Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Andrew R. Miksztal, Hongwei Wu, Min L. Lee
Filed: 28 Jun 22
Utility
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
20 Dec 22
The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent.
Michael Sekar, Felix Theeuwes, Keith Edward Branham, John W Gibson, James Matriano, Whitney Moro, John Tipton, William Van Osdol, Su Il Yum
Filed: 21 Jul 20
Utility
Treatment of Alcoholic Hepatitis
1 Dec 22
Methods of treating alcoholic hepatitis (AH) are provided.
WEIQI LIN, JAMES E. BROWN, TERRENCE BLASCHKE
Filed: 29 Sep 20
Utility
Compositions and Methods Involving Polymer, Solvent and High Viscosity Liquid Carrier Material
8 Sep 22
Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent.
Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
Filed: 14 Feb 22
Utility
Sustained Release Drug Delivery Systems with Reduced Impurities and Related Methods
1 Sep 22
The present disclosure relates to sustained release drug delivery systems.
ANDREW R. MIKSZTAL, JUDY JOICE, SUSAN AUTIO, MARK P. DAVIS
Filed: 21 Jan 22
Utility
Sustained Release Drug Delivery Systems and Related Methods
1 Sep 22
The present disclosure provides for methods of producing analgesia in a subject.
ADRIAN NEIL VERITY, STEVEN HALLADAY, VAELING MILLER, PETER LANGECKER, DMITRI LISSIN, ANDREW R. MIKSZTAL, JUDY JOICE, SUSAN AUTIO, MARK P. DAVIS
Filed: 13 May 22